Oncolytic virotherapy: basic principles, recent advances and future directions

D Lin, Y Shen, T Liang - Signal transduction and targeted therapy, 2023 - nature.com
Oncolytic viruses (OVs) have attracted growing awareness in the twenty-first century, as they
are generally considered to have direct oncolysis and cancer immune effects. With the …

Combination strategies to maximize the benefits of cancer immunotherapy

S Zhu, T Zhang, L Zheng, H Liu, W Song, D Liu… - Journal of hematology & …, 2021 - Springer
Immunotherapies such as immune checkpoint blockade (ICB) and adoptive cell therapy
(ACT) have revolutionized cancer treatment, especially in patients whose disease was …

Oncolytic viruses for cancer immunotherapy

O Hemminki, JM Dos Santos, A Hemminki - Journal of hematology & …, 2020 - Springer
In this review, we discuss the use of oncolytic viruses in cancer immunotherapy treatments in
general, with a particular focus on adenoviruses. These serve as a model to elucidate how …

Optimizing oncolytic virotherapy in cancer treatment

K Harrington, DJ Freeman, B Kelly, J Harper… - Nature reviews Drug …, 2019 - nature.com
In the wake of the success of modern immunotherapy, oncolytic viruses (OVs) are currently
seen as a potential therapeutic option for patients with cancer who do not respond or fail to …

Oncolytic viruses as engineering platforms for combination immunotherapy

K Twumasi-Boateng, JL Pettigrew, YYE Kwok… - Nature Reviews …, 2018 - nature.com
To effectively build on the recent successes of immune checkpoint blockade, adoptive T cell
therapy and cancer vaccines, it is critical to rationally design combination strategies that will …

Artificial intelligence and machine learning approaches for drug design: challenges and opportunities for the pharmaceutical industries

C Selvaraj, I Chandra, SK Singh - Molecular diversity, 2021 - Springer
The global spread of COVID-19 has raised the importance of pharmaceutical drug
development as intractable and hot research. Developing new drug molecules to overcome …

Bispecific antibodies: design, therapy, perspectives

SE Sedykh, VV Prinz, VN Buneva… - Drug design …, 2018 - Taylor & Francis
Antibodies (Abs) containing two different antigen-binding sites in one molecule are called
bispecific. Bispecific Abs (BsAbs) were first described in the 1960s, the first monoclonal …

Oncolytic viral therapy and the immune system: a double-edged sword against cancer

G Marelli, A Howells, NR Lemoine, Y Wang - Frontiers in immunology, 2018 - frontiersin.org
Oncolytic viral therapy is a new promising strategy against cancer. Oncolytic viruses (OVs)
can replicate in cancer cells but not in normal cells, leading to lysis of the tumor mass …

CARs versus BiTEs: a comparison between T cell–redirection strategies for cancer treatment

CY Slaney, P Wang, PK Darcy, MH Kershaw - Cancer Discovery, 2018 - AACR
The redirection of T cells against tumors holds much promise for the treatment of cancer.
Two main approaches for T-cell redirection involve their genetic modification with chimeric …

Combining oncolytic viruses with cancer immunotherapy: establishing a new generation of cancer treatment

T Shi, X Song, Y Wang, F Liu, J Wei - Frontiers in immunology, 2020 - frontiersin.org
The recent successes of tumor immunotherapy approaches, such as immune checkpoint
blockade (ICB) and chimeric antigen receptor T cell (CAR-T) therapy, have revolutionized …